D-Serine
- Generic Name
- D-Serine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C3H7NO3
- CAS Number
- 312-84-5
- Unique Ingredient Identifier
- 1K77H2Z9B1
- Background
A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids. [PubChem]
- Associated Conditions
- -
- Associated Therapies
- -
D-serine AudRem: R33 Phase
- Conditions
- Interventions
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 60
- Registration Number
- NCT05046353
- Locations
- 🇺🇸
NYSPI, New York, New York, United States
A Study to Compare the Safety, Tolerability, and Pharmacokinetics of CTP-692 Versus D-serine in Healthy Volunteers
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Concert Pharmaceuticals
- Target Recruit Count
- 13
- Registration Number
- NCT03778320
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, South Australia, Australia
D-serine Augmentation of Neuroplasticity
- Conditions
- Interventions
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 45
- Registration Number
- NCT03711500
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
🇺🇸Nathan Kline Institute, Orangeburg, New York, United States
D-serine and Cognitive Remediation in Schizophrenia
- First Posted Date
- 2014-06-05
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Nathan Kline Institute for Psychiatric Research
- Target Recruit Count
- 8
- Registration Number
- NCT02156908
- Locations
- 🇺🇸
Nathan Kline Institute, Orangeburg, New York, United States
D-Serine for Cocaine Dependence Pilot
- Conditions
- Interventions
- First Posted Date
- 2012-10-26
- Last Posted Date
- 2014-02-06
- Lead Sponsor
- Theresa Winhusen
- Registration Number
- NCT01715051
- Locations
- 🇺🇸
Maryhaven, Inc, Columbus, Ohio, United States
N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2011-11-18
- Last Posted Date
- 2012-10-25
- Lead Sponsor
- Nathan Kline Institute for Psychiatric Research
- Target Recruit Count
- 16
- Registration Number
- NCT01474395
- Locations
- 🇺🇸
Nathan Kline Insitute for Psychiatric Research, Orangeburg, New York, United States
High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia
- First Posted Date
- 2011-10-25
- Last Posted Date
- 2011-10-25
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 54
- Registration Number
- NCT01459029
- Locations
- 🇮🇱
Ezrath Nashim - Herzog Memorial Hospital & Community Clinics, Jerusalem, Israel
🇮🇱Hadassah Medical Organization, Jerusalem, Israel
Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
- First Posted Date
- 2009-11-23
- Last Posted Date
- 2018-01-30
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 39
- Registration Number
- NCT01018056
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
D-serine for the Schizophrenia Prodrome
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2017-08-14
- Lead Sponsor
- Nathan Kline Institute for Psychiatric Research
- Target Recruit Count
- 44
- Registration Number
- NCT00826202
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸Zucker Hillside Hospital, Glen Oaks, New York, United States
🇺🇸New York State Psychiatric Institute, New York, New York, United States
D-serine Monotherapy for Schizophrenia
- First Posted Date
- 2009-01-05
- Last Posted Date
- 2013-12-10
- Lead Sponsor
- Herzog Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT00816894
- Locations
- 🇮🇱
Ezrath Nashim - Herzog Memorial Hospital, Jerusalem, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.